Nicholas Gilbo

Surgeon.
Lover of all things science. Organ preservation, transplantation, and regeneration in particular.
Torino 🇮🇹 Liège 🇧🇪

[Nicholas Gilbo @NicholasGilbo]

Honored to be among the first authors of this spectacular team work & very proud to have led the #LiverTransplant arm of this study!
We have shown that #ferroptosis is a promising therapeutic target to safely transplant high-risk grafts!
Thx @CellCellPress for the highlight!

[Cell @CellCellPress]

Now online! Ferroptosis inhibition enhances liver and lung graft function https://t.co/zSkNPumIzv

[Nicholas Gilbo @NicholasGilbo]

1/ 🧵 I had the honor of leading the #liver arm of a new study just out in @CellCellPress, and I'll say it plainly: the liver data were spectacular! https://t.co/IAsS3w9coe
A single ferroptosis inhibitor given through cold flush and static storage, rescued high-risk DCD grafts!

[Nicholas Gilbo @NicholasGilbo]

7/ Thanks to an extraordinary consortium and in particular to @TomVBerghe for involving me in this project and making me discover this exciting new avenue of translational research in #livertransplantation

[Nicholas Gilbo @NicholasGilbo]

1/ 🧵 I had the honor of leading the #liver arm of a new study just out in @CellCellPress, and I'll say it plainly: the liver data were spectacular! https://t.co/IAsS3w9coe
A single ferroptosis inhibitor given through cold flush and static storage, rescued high-risk DCD grafts!

[Nicholas Gilbo @NicholasGilbo]

6/❓What's next for the liver group.
@GIGA_ULiege and #CREDECLab we're now pushing ferroptosis inhibition into the harder problems:
🔵steatotic liver reconditioning under long-term MP
🔵cholangiocellular IRI — the silent driver of late failure
🔵Aim: a first-in-human trial!

[Nicholas Gilbo @NicholasGilbo]

Honored to have my @frsFNRS postdoc fellowship renewed!
Grateful for the chance to explore:
🧫 #organoids & cholangiopathy
⚙️ Split liver #NMP
🧲 Ferroptosis in transplant
💥 Resensitizing CCA
Exciting work ahead — thanks for the support! #TransplantResearch

[Nicholas Gilbo @NicholasGilbo]

2/ Incredible science, meaningful conversations, and lots of memorable moments — including our team photo 📸

Huge thanks to @ESOTtransplant for an outstanding congress.
Already looking forward to #ESOT2027 in Prague!

[Nicholas Gilbo @NicholasGilbo]

1/ #ESOT2025 comes to a close!
Our team @CHULiege & #CREDEC was proud to contribute — from building the 🇪🇺 machine perfusion registry to presenting research & lectures on:
🔮the future of organ assessment & repair
🧫 Cholangiocyte #organoids
🧬 MSC therapy during kidney #NMP

[ESOTtransplant @ESOTtransplant]

Exciting news!
🌍 We are launching a new membership to make our programmes accessible to healthcare professionals in low- and middle-income countries.

Let’s create opportunities together because talent knows no borders!

#PoweredByESOT w/ @gabriel_oniscu

[Nicholas Gilbo @NicholasGilbo]

When survival of pt w/ unresectable CRC #liver mts gets better than pt w/ resected mts you start asking yourself if we have the moral obligation to offer #LT to all CRC mts despite the limited donor pool... Groundbreaking study & exciting new research ahead! #TransplantOncology

[Arndt Vogel @ArndtVogel]

Liver transplantation + CTx vs CTx in unresectable CRC liver metastases
🔎TransMet randomised trial
@TheLancet
https://t.co/AiOnFYzy0e
👉5-yr OS: 56.6 vs 12.6%
👉Recurrence after LTx: 72%
🧐Impressive study, impressive results
❗️LTx valid option in highly selected pts
@myESMO @EASLedu @ILCAnews #livertwitter

[Nicholas Gilbo @NicholasGilbo]

@ArndtVogel @HepatomaRes @TheLancet @myESMO When survival of patients with unresectable CRC liver mets gets better than those with resected mets you start asking yourself whether we have the moral obligation to offer LT to all CRC mets despite the limited donor pool... Groundbreaking study and exciting new research ahead!

[Nicholas Gilbo @NicholasGilbo]

Honored to be awarded a Lecturer position in clinical medicine at @UniversiteLiege!
Thanks to the Rector and Faculty of Medicine for this opportunity & the insightful welcome seminar.
Excited to inspire students in #AcademicSurgery & #transplant research!
https://t.co/ItG0V0TmKV

[ESOTtransplant @ESOTtransplant]

On 29 August, the 11th Living Donor Abdominal Conference will kick off with the 3rd Workshop on Living Donation that focuses on #ESOT_YPT to discuss about living organ donation in the presence of senior faculty from Europe, USA and Asia. Following the Workshop, participants are invited to attend the subsequent main conference on 30 and 31 August 2024 for free.

Applications deadline: Monday, 1 July! More information ⤵️

Endorsement #PoweredByESOT
@frank_dor @DabareDilan @CDudreuilh @LornaMarson @Lucreziafurian @ValeriaMas11

https://t.co/wg3mP2aVx1

[Nicholas Gilbo @NicholasGilbo]

@ArndtVogel @Annals_Oncology @myESMO We should resect the primitive of those with unresectable liver only mets and list them for #livertransplantation !

[Burcin Ekser, MD, PhD @BurcinEkser]

Liver @xenotransplantation. Better and more exciting news to come soon…
@ASTSChimera @_ILTS_ @AASLDtweets
@islsstudygroups @ttsorg @SPLIT_TTS @IXAYIC

First pig-to-human liver transplant recipient 'doing very well' https://t.co/5uvhTlat4w

[Nicholas Gilbo @NicholasGilbo]

🔚: there is more than meets the eye!!!
🟢 The relation of #NMP & inflammation is complex
🟢 Severity of ischemic injury & timing of NMP may affect inflammation “on-pump”
🟢 Early NMP may better preserve DCDs.

🔜 the next study?
Inflammation in continuous ↔️ end-ischemic NMP!

[Nicholas Gilbo @NicholasGilbo]

💡Main takeaways:

1️⃣ Pre-existing injury, especially WI, affects inflammation during NMP
2️⃣ Continuous #liverNMP reduces inflammation even with severe WI injury
3️⃣ Unlike in end-ischemic NMP, where pro-inflammatory cytokines peak early and are higher in DCD than DBD livers
7/n